PME
04/07/26
..................
ASX:PME (Pro Medicus) has delivered exceptional growth over the past 5 years, compounding profits at a 39% annual rate and seeing its Return on Equity (ROE) steadily increase to exceed 50%. The company remains virtually debt-free with a cash-heavy balance sheet, though its valuation multiples remain very high. [1, 2, 3, 4, 5]
Profit & Revenue
- Massive Growth: Net Profit After Tax (NPAT) has grown consistently, jumping from roughly A$31 million three years ago to record highs exceeding A$115 million in recent periods. [1, 2, 3]
- Margins: The company boasts industry-leading margins, with net profit margins exceeding 50% and gross margins approaching nearly 100% due to its scalable, cloud-based transaction model. [1, 2, 3, 5]
Debt & Financial Health
Return on Equity (ROE)
- Top-Tier Returns: PME's ROE has trended upwards over the last 5 years, starting at around 43.5% in 2021 and scaling up to approximately 51.8% to 76.8% in recent tracking periods. This reflects outstanding capital efficiency. [1, 2]
Stock Performance & Valuation
- 5-Year Returns: Driven by ongoing US contract wins and a strong pipeline, the PME share price climbed roughly 263% over the past 5 years, though it has experienced volatility more recently. [1, 2, 3, 4, 5]
- Valuation: Because of its high quality, PME typically trades at a premium—historically commanding a high Price-to-Earnings (P/E) ratio (e.g., in the 90s range). [1, 2, 3, 4]
======================================
PE ratios
The 10-year historical average Price-to-Earnings (P/E) ratio for Pro Medicus Limited (ASX: PME) is approximately 131.38. [1]
As an elite ASX growth engine, Pro Medicus commands an exceptionally high multiple due to its dominant enterprise medical imaging software and consistent near-70% operating margins. Its P/E ratio expanded dramatically alongside rapid contract wins in North America, peaking at over 250x in late FY25 before compressing back to ~91.6x as of July 2026 following a broader tech market derating. [1, 2, 3, 4, 5]
Historical P/E Ratio Data (Year-End)
| Year [1, 2, 3, 4, 5, 6] | Approximate P/E Ratio (TTM) | Valuation Context |
|---|---|---|
| Current (Jul 2026) | 91.6x | Valuation compression post-HY26 tech sector pullback. |
| 2025 | 258.5x | All-time valuation high; hyper-growth pricing over software expansion. |
| 2024 | 179.0x | Massive expansion driven by landmark Tier-1 US hospital contract wins. |
| 2023 | 120.0x | Rebound after a brief growth stock cyclical low. |
| 2022 | 100.0x | Broad market valuation compression due to rising global interest rates. |
| 2021 | 179.5x | Post-pandemic digital health boom peak acceleration. |
| 2020 | 128.0x | Strong enterprise contract momentum despite pandemic disruptions. |
| 2019 | 102.0x | Crosses the triple-digit threshold as Visage 7 software adoption scales. |
| 2018 | 78.0x | High growth multiples begin establishing as SaaS revenue shifts. |
| 2017 | 65.0x | Inflection point following early major US healthcare network wins. |
| 2016 | 58.5x | The 10-year historical minimum multiple base layer. |
-----------------------------
DIV
.........................
ROIC vs WACC
Pro Medicus (ASX:PME) maintains an exceptionally high ROIC (around 62% to 74%) that massively exceeds its WACC (roughly 7.5% to 13.8%), demonstrating extraordinary and consistent value creation over the last decade. [1, 2, 3]
Return on Invested Capital (ROIC)
- Current/Recent Level: ~62.4% to 74.1%.
- 10-Year Trend: PME has experienced an extraordinary upward trajectory in capital efficiency. Driven by high-margin software contracts (Visage 7) and minimal heavy physical asset requirements, its returns on equity and capital have scaled dramatically from lower levels a decade ago to peak consistently above 50%–70%. [1, 2, 3, 4, 5]
Weighted Average Cost of Capital (WACC)
- Current/Recent Level: ~7.6% to 13.8% depending on shifting market risk-free rates and beta models.
Economic Value Spread (ROIC vs. WACC)
- Massive Positive Spread: Because PME's ROIC (>60%) sits vastly above its WACC (~8%–13%), the company creates enormous economic value.
...............
Argo Investments (ASX:ARG) and Pro Medicus (ASX:PME) represent opposite ends of the investing spectrum. [1]
- Argo (ARG) is a conservative Listed Investment Company (LIC) that acts like a proxy for the broader Australian market. [1]
A side-by-side metric comparison establishes their contrasting profiles, followed by a Warren Buffett-style evaluation of both companies.
Head-to-Head Metrics
| Metric | Argo Investments (ASX:ARG) | Pro Medicus (ASX:PME) |
|---|---|---|
| Core Business | Diversified Investment Portfolio (LIC) | Cloud Medical Imaging Software |
| 10-Year Capital Growth | Low (~26.6% cumulative share price gain) | Hyper-growth (>1,500% cumulative gain) |
| P/E Ratio | 26.5 | 63.2 |
| Current Dividend Yield | 4.2% (approx. 6.0% grossed up) | 0.43% |
| 10-Year Dividend Growth | Slow (~2.7% CAGR) | Explosive (~30.0% CAGR) |
| Franking | 100% Fully Franked | 100% Fully Franked |
The Buffett Style Breakdown --- ARG vs PME sept 2026
Warren Buffett’s investment framework prioritizes competitive moats, predictable earnings, excellent capital allocation, and a fair price. Examining how both assets fit the Berkshire Hathaway philosophy reveals their fundamental differences.
1. Economic Moat & Business Model
- ARG: Argo has no structural economic moat, as anyone can buy the index or underlying blue-chip stocks. Its strength lies in a highly reliable, low-cost operating model (Management Expense Ratio of just 0.14%) and an exceptionally long track record of surviving economic cycles. [1, 2]
- PME: Buffett would highly admire Pro Medicus’s business model. It possesses a wide technological moat with its industry-leading Visage 7 cloud imaging platform. It is heavily integrated into major tier-1 hospital systems globally, leading to incredibly high switching costs. Crucially, it is capital-light, spending less than A$500,000 annually on physical assets, meaning nearly 100% of accounting profits flow straight into cash. [1, 2, 3]
2. Earnings and Growth
- ARG: Earnings are tethered entirely to the cyclical dividends of large Australian banks and miners. Earnings have grown slowly at roughly 1% per year over the past 5 years. It does not compound internal cash; it pays out nearly everything it takes in.
- PME: Possesses the explosive compounding power Buffett looks for in exceptional businesses. Net income margin sits at a staggering 101% (boosted by abnormal accounting credits/adjustments in FY26), with organic revenues growing at 25-30% annually. It retains the majority of its cash (~28% payout ratio) to fund future expansions and AI integration. [1, 2, 3, 4, 5, 6]
3. Dividend Performance & "Yield on Cost"
- ARG: This is a classic "income now" stock. It yields a strong 4.2% base, but because its dividend growth is sluggish (~2.7% CAGR), it barely beats inflation over a 10-year stretch.
- PME: While the headline yield is a tiny 0.43%, its dividend growth rate is 30% per year. This reflects Buffett's concept of growing intrinsic value. An investor who bought PME 10 years ago is now enjoying a massive "yield on cost"—meaning their annual dividend checks today might represent a 20% to 50% return relative to their original small initial investment. [1, 2, 3, 4]
4. Valuation ("Margin of Safety")
- ARG: Trading near its Net Tangible Assets (NTA) value, meaning you pay a fair, predictable price for the underlying liquid assets.
- PME: This is where the Buffett thesis faces a hurdle. At a P/E of over 63x, the market builds massive growth expectations into the price. While the business quality is elite, buying at this premium squeezes your "Margin of Safety," leaving the stock vulnerable to sharp corrections if future growth slows down even slightly. [1, 2, 3, 4, 5]
The Verdict
- Argo (ARG) aligns with the automated, "hands-off" index fund style that Buffett recommends for 99% of defensive investors who prioritize immediate income and stability.
...................
Pro Medicus Ltd (ASX: PME) stands out as one of the highest-quality compounders on the ASX. [1]
When evaluated through a strict Buffett framework, its metrics do not just pass—they place the company in an elite tier of global corporate profitability.
A multi-dimensional breakdown explores PME's historical Return on Equity (ROE) and capital allocation practices against Warren Buffett’s core investment benchmarks.
1. Historical ROE Trends vs. Buffett’s Yardstick
Warren Buffett looks for companies that can maintain an average ROE above 20% over 10 years, with no single year dropping below 15%. [1]
- The Reality for PME: PME leaves this benchmark far behind. Its historical ROE consistently exceeds 50%, tracking as high as 74.97% in recent 2026 reports. [1, 2]
- The Drivers (DuPont Analysis): High ROE can sometimes be artificially inflated by excessive debt. However, PME has virtually zero debt, meaning its stellar ROE is entirely driven by its 49% net profit margins and an incredibly capital-light business model. The company generates huge earnings relative to a very small base of physical or equity capital. [1, 2]
2. Capital Allocation Decisions vs. Buffett Benchmarks
Buffett evaluates capital allocation by looking at how well a management team deploys retained earnings to generate incremental shareholder value.
| Buffett Benchmark Criteria | Standard Requirement | Pro Medicus (ASX: PME) Performance | Evaluation |
|---|---|---|---|
| High Gross Profit Margins | At least 40% | Routinely surpasses 80-90% given its software-as-a-service (SaaS) architecture. Net margins sit around 49%. | Exceptional |
| The $1 Test (Retained Earnings) | Every $1 retained must create at least $1 in market value. | Over the past decade, PME has been a top ASX performer (~71% annualized return). Retained earnings have been translated exponentially into market cap growth. | Exceptional |
| Organic Reinvestment Opportunity | High Return on Invested Capital (ROIC). | ROIC sits comfortably between 44% and 68.62%. Management scales via R&D and contract wins rather than heavy capital expenditure. | Exceptional |
| Conservative Financial Leverage | Minimal debt-to-equity ratio. | Maintains a near-pristine balance sheet with no structural debt. | Exceptional |
Reinvestment vs. Dividends
Because its core software product (Visage 7) is highly scalable, PME requires very little capital to onboard massive new hospital networks. Consequently, management faces a "good problem": they cannot physically reinvest all their cash into the business without diminishing their elite ROIC. To counter this, they efficiently distribute unneeded capital back to shareholders through a steady, rising dividend payout, matching Buffett's rule of returning capital when internal compounding slows down. [1, 2]
The Buffett Catch: The Valuation Paradox
Buffett insists on a margin of safety. Historically, PME trades at a Price-to-Earnings (P/E) ratio well over 150x. While approximately 80% of its long-term share price appreciation has been driven by real earnings growth, the extreme valuation multiple means investors are paying an absolute premium for this quality. [1]
...........
No comments:
Post a Comment